Increasing evidence that the risks of rhAPC may outweigh its benefits

This publication has 10 references indexed in Scilit:

• Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study
  Intensive Care Medicine, 2007
• Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey
  Intensive Care Medicine, 2007
• First, Gather the Data
  New England Journal of Medicine, 2006
• The Value of Phase 4 Clinical Testing
  New England Journal of Medicine, 2006
• Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*
  Critical Care Medicine, 2005
• Reassessing recombinant human activated protein C for sepsis: Time for a new randomized controlled trial*
  Critical Care Medicine, 2005
• Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
  New England Journal of Medicine, 2005
• Substantiating the concerns about recombinant human activated protein C use in sepsis*
  Critical Care Medicine, 2004
• Recombinant human activated protein C in sepsis: Inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials
  Critical Care Medicine, 2003
• Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
  New England Journal of Medicine, 2001